127 related articles for article (PubMed ID: 33023949)
1. A Global and Integrated Analysis of CINSARC-Associated Genetic Defects.
Lesluyes T; Chibon F
Cancer Res; 2020 Dec; 80(23):5282-5290. PubMed ID: 33023949
[TBL] [Abstract][Full Text] [Related]
2. CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond.
Chibon F; Lesluyes T; Valentin T; Le Guellec S
Genes Chromosomes Cancer; 2019 Feb; 58(2):124-129. PubMed ID: 30387235
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
[TBL] [Abstract][Full Text] [Related]
4. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.
Lagarde P; Przybyl J; Brulard C; Pérot G; Pierron G; Delattre O; Sciot R; Wozniak A; Schöffski P; Terrier P; Neuville A; Coindre JM; Italiano A; Orbach D; Debiec-Rychter M; Chibon F
J Clin Oncol; 2013 Feb; 31(5):608-15. PubMed ID: 23319690
[TBL] [Abstract][Full Text] [Related]
5. RNA sequencing validation of the Complexity INdex in SARComas prognostic signature.
Lesluyes T; Pérot G; Largeau MR; Brulard C; Lagarde P; Dapremont V; Lucchesi C; Neuville A; Terrier P; Vince-Ranchère D; Mendez-Lago M; Gut M; Gut I; Coindre JM; Chibon F
Eur J Cancer; 2016 Apr; 57():104-11. PubMed ID: 26916546
[TBL] [Abstract][Full Text] [Related]
6. Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03).
Jakob J; Lesluyes T; Simeonova-Chergou A; Wenz F; Hohenberger P; Chibon F; Le Guellec S
Strahlenther Onkol; 2020 Mar; 196(3):280-285. PubMed ID: 31732782
[TBL] [Abstract][Full Text] [Related]
7. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
Bertucci F; Niziers V; de Nonneville A; Finetti P; Mescam L; Mir O; Italiano A; Le Cesne A; Blay JY; Ceccarelli M; Bedognetti D; Birnbaum D; Mamessier E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017155
[TBL] [Abstract][Full Text] [Related]
8. The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms.
Lesluyes T; Delespaul L; Coindre JM; Chibon F
Sci Rep; 2017 Jul; 7(1):5480. PubMed ID: 28710396
[TBL] [Abstract][Full Text] [Related]
9. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
10. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.
Chibon F; Lagarde P; Salas S; Pérot G; Brouste V; Tirode F; Lucchesi C; de Reynies A; Kauffmann A; Bui B; Terrier P; Bonvalot S; Le Cesne A; Vince-Ranchère D; Blay JY; Collin F; Guillou L; Leroux A; Coindre JM; Aurias A
Nat Med; 2010 Jul; 16(7):781-7. PubMed ID: 20581836
[TBL] [Abstract][Full Text] [Related]
11. Complexity index in sarcoma and genomic grade index gene signatures in rhabdomyosarcoma of pediatric and adult ages.
Ferrari A; Iannó MF; Carenzo A; Fortunato O; Casanova M; Chiaravalli S; Bergamaschi L; Bertulli R; Cattaneo F; Collini P; Trama A; Sozzi G; Massimino M; De Cecco L; Gasparini P
Pediatr Blood Cancer; 2021 Jul; 68(7):e28987. PubMed ID: 33751795
[TBL] [Abstract][Full Text] [Related]
12. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
Bertucci F; De Nonneville A; Finetti P; Perrot D; Nilbert M; Italiano A; Le Cesne A; Skubitz KM; Blay JY; Birnbaum D
Ann Oncol; 2018 Feb; 29(2):459-465. PubMed ID: 29069276
[TBL] [Abstract][Full Text] [Related]
13. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
Frezza AM; Stacchiotti S; Chibon F; Coindre JM; Italiano A; Romagnosa C; Bagué S; Dei Tos AP; Braglia L; Palmerini E; Quagliuolo V; Broto JM; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Beveridge RD; Lugowska I; Lesluyes T; Maestro R; Merlo FD; Casali PG; Gronchi A
Cancer Med; 2023 Jan; 12(2):1350-1357. PubMed ID: 35848358
[TBL] [Abstract][Full Text] [Related]
14. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers.
Fujiwara T; Kunisada T; Takeda K; Uotani K; Yoshida A; Ochiya T; Ozaki T
Biomed Res Int; 2014; 2014():592868. PubMed ID: 25165708
[TBL] [Abstract][Full Text] [Related]
16. Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas.
Wong P; Hui A; Su J; Yue S; Haibe-Kains B; Gokgoz N; Xu W; Bruce J; Williams J; Catton C; Wunder JS; Andrulis IL; Gladdy R; Dickson B; O'Sullivan B; Liu FF
Oncotarget; 2015 Nov; 6(36):39127-39. PubMed ID: 25970788
[TBL] [Abstract][Full Text] [Related]
17. Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease.
Vargas AC; Gray LA; White CL; Maclean FM; Grimison P; Ardakani NM; Bonar F; Algar EM; Cheah AL; Russell P; Mahar A; Gill AJ
Sci Rep; 2021 Jan; 11(1):667. PubMed ID: 33436720
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of prognostic markers in sarcomas base on a multi-omics analysis.
Song Y; Yang K; Sun T; Tang R
BMC Med Genomics; 2021 Jan; 14(1):31. PubMed ID: 33509178
[TBL] [Abstract][Full Text] [Related]
19. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.
Goncalves A; Finetti P; Birnbaum D; Bertucci F
NPJ Breast Cancer; 2021 May; 7(1):48. PubMed ID: 33953185
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells.
Jemaà M; Abdallah S; Lledo G; Perrot G; Lesluyes T; Teyssier C; Roux P; van Dijk J; Chibon F; Abrieu A; Morin N
Oncotarget; 2017 Mar; 8(10):16669-16689. PubMed ID: 28035071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
